Abstract
To study if cabergoline, a long-lasting specific dopamine D2 receptor agonist, has neuroprotective effects against oxidative stress, we exposed (3 h) SH-SY5Y human neuroblastoma cells to tert-butylhydroperoxide (t-BOOH; 500 microM). t-BOOH caused a 42+/-4% neuronal death, which was prevented by cabergoline (2 h before) in a concentration-dependent manner (EC(50): 1.24 microM). This effect was not antagonised by haloperidol (concentration up to 10 microM), and was associated with an increased availability of intracellular GSH contents (+30+/-11%) and a decrease in the membrane lipid peroxidation (-23+/-9%). Our data suggest that cabergoline has neuroprotective effects useful for Parkinson's disease therapy.
MeSH terms
-
Cabergoline
-
Cell Death / drug effects
-
Cell Survival / drug effects
-
Dopamine Agonists / pharmacology*
-
Dopamine Antagonists / pharmacology
-
Dopamine D2 Receptor Antagonists
-
Dose-Response Relationship, Drug
-
Ergolines / pharmacology*
-
Free Radicals / metabolism
-
Haloperidol / pharmacology
-
Humans
-
Lipid Peroxidation / drug effects
-
Models, Neurological
-
Necrosis
-
Neurons / drug effects*
-
Neurons / pathology
-
Neuroprotective Agents / pharmacology*
-
Oxidative Stress / drug effects*
-
Parkinson Disease / metabolism
-
Parkinson Disease / prevention & control
-
Receptors, Dopamine D2 / agonists
-
Tumor Cells, Cultured
-
tert-Butylhydroperoxide / toxicity
Substances
-
Dopamine Agonists
-
Dopamine Antagonists
-
Dopamine D2 Receptor Antagonists
-
Ergolines
-
Free Radicals
-
Neuroprotective Agents
-
Receptors, Dopamine D2
-
tert-Butylhydroperoxide
-
Haloperidol
-
Cabergoline